FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

The U.S. Food and Drug Administration approval of ibrutinib (Imbruvica) to treat patients with Waldenstrom's macroglobulinemia(WM) is a significant advance for patients with this rare blood cancer.



from The Medical News http://ift.tt/1ziRmiS